Previous 10 | Next 10 |
Poster #1: Tri-specific killer engagers target natural killer cells towards mesothelioma Poster #2: Enhancing NK cell function in the 'cold' tumor microenvironment of prostate cancer with a novel Tri-specific Killer Engager against prostate-specific membrane antigen (PSMA) BRISB...
BRISBANE, CALIFORNIA, Nov. 03, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary natural killer (NK...
GT Biopharma press release ( NASDAQ: GTBP ): Q3 GAAP EPS of -$0.22 misses by $0.11 . $20.8 million in cash, cash equivalents and short-term investments as of September 30, 2022, is expected to provide runway to fund operations into 2023. For further details see: ...
Announced two poster presentations at the Society for Immunotherapy of Cancer’s 37th Annual Meeting (SITC 2022) $20.8 million in cash, cash equivalents and short-term investments as of September 30, 2022, is expected to provide runway to fund operations into 2023. BRISBAN...
Brisbane, California--(Newsfile Corp. - October 25, 2022) - GT Biopharma, Inc. ( NASDAQ: GTBP ) (the "Company" or "GTB"), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE ...
GT Biopharma ( NASDAQ: GTBP ) has filed for a $150M mixed shelf offering . The filing does not necessarily indicate that a sale has begun, or will occur in the future. The company intends to use the proceeds for general corporate purposes. The offering can...
BRISBANE, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary natural killer (NK) ce...
- Meeting adjourned to October 10, 2022 at 11 a.m. PST - GTB encourages all stockholders of record on August 8, 2022 who have not yet voted - to do so by 11:59 p.m. PST Time on October 9, 2022 BRISBANE, CALIFORNIA, Oct. 04, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the ȁ...
GTB-5550 generates a robust and NK cell specific proliferation signal compared to IL-15 alone GTB-5550 specifically targets B7-H3+ cells GTB-5550 effectively induced NK cell degranulation and interferon gamma production in response to various prostate, brain tumor (atypical rhabdo...
BRISBANE, Calif., Sept. 08, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE ® platform, today announced that...
News, Short Squeeze, Breakout and More Instantly...
GTB-3650 Phase 1 trial initiation expected in H2 2024; initial clinical data expected in H1 2025 GTB-5550 TriKE ® IND submission for treatment of B7H3 positive solid tumors expected in Q1 2025 GTB-5550 Phase 1 dose escalation basket trial initiation expected in 20...
BRISBANE, CALIFORNIA, May 21, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP) (the “Company”), today announced that it has entered into a definitive securities purchase agreements for the purchase and sale of 740,000 shares of the Company’s common stock at a purcha...
A look at the top 10 most actives in the United States Crown Electrokinetics Corp. (CRKN) rose 16.4% to $0.199 on volume of 720,586,242 shares Faraday Future Intelligent Electric Inc. (FFIE) rose 74.8% to $1.8 on volume of 682,362,254 shares Pineapple Energy Inc. (PEGY) rose 80.3% to $0.1...